Lipid Buildup Linked to Lung Scarring in Mice

UCLA researchers found that dysregulated fat handling in lung immune cells may drive pulmonary fibrosis, a progressive scarring disease.

Updated on Nov. 10, 2026 in Asthma

Close macro view of a glass petri dish and steel microscope stage on a white tile, with pale pink lung tissue slices beside them. — UCLA researchers found that dysregulated fat handling in lung immune cells may drive pulmonary fibrosis in mice, a progressive scarring disease. AI Illustration. Upload story photo >

Live Poll

Would you want a blood test to detect early lung scarring risk?

UCLA Health researchers identified lipid dysregulation in alveolar macrophages as a potential trigger for pulmonary fibrosis in mice. Restoring macrophage lipid handling almost completely protected the mice from fibrosis.

Why it matters

Pulmonary fibrosis leads to respiratory failure and high mortality, and current therapies mainly slow progression once scarring is established. Identifying an early driver of the disease may open paths to earlier detection and intervention.

In the study, mice lacking the ABCG1 protein accumulated lipids in alveolar macrophages before other biological changes appeared in the lungs, compared with normal mice. Whether these findings translate to human pulmonary fibrosis remains unconfirmed.

The players

UCLA Health

The University of California, Los Angeles health system is a major academic medical center in California that conducted the research.

The details

Researchers found that lipids in alveolar macrophages directly signal neighboring fibroblasts to activate and produce scar tissue. Transferring ABCG1-deficient bone marrow into otherwise normal mice promoted fibrosis, and the work was published in Am J Respirat Cell Mol Biol.

2026: Study published in Am J Respirat Cell Mol Biol

Health Landscape

Earlier UCLA studies found that lipids in the lungs of patients with autoimmune pulmonary alveolar proteinosis and idiopathic pulmonary fibrosis were associated with disease burden and decreased lung function. This work moves that association toward a proposed causal mechanism, though it remains preclinical.

Current pulmonary fibrosis treatments primarily slow progression once scarring is already established. Detecting lipid changes at earlier stages could eventually help identify patients at increased risk, though no clinical test exists yet.

The takeaway

Early changes in how lung immune cells handle fat may precede visible scarring in pulmonary fibrosis. Tracking such markers could become a future route to earlier detection, pending human studies.